Related Experiment Videos
Protective Effect of Xuebijing Injection on Gastrointestinal Function in Septic Patients of Non-Gastrointestinal
Fang Li1, Rui Wang1, Tingting Ding1
1Intensive Care Unit, Ningbo Zhenhai Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, 315200, People's Republic of China.
Objective:
The purpose of this study was to assess the 28-day prognosis and gastrointestinal protection of early Xuebijing in non-gastrointestinal sepsis.
Methods:
Septic patients with infection origins outside the gastrointestinal system and no history of acute gastrointestinal injury (AGI) were included in this single-center retrospective analysis. The two groups' baseline characteristics were balanced by propensity score matching (PSM). Secondary objectives were organ function, enteral nutrition tolerance, inflammatory markers, AGI onset time, and clinical outcomes. The primary endpoint was the incidence of 28-day AGI.
Results:
After matching, each group had 87 patients, and the baseline variables were evenly distributed among them (P > 0.05). The 28-day cumulative AGI rate for the Xuebijing group was 44.8%, which was considerably lower than the control group's rate of 69.0% (P = 0.002). Additionally, there was a significant delay in the beginning of AGI in the treated group (log-rank P < 0.001). Furthermore, Xuebijing treatment resulted in shorter hospital and ICU stays as well as larger drops in CRP, PCT, and SOFA ratings (all between-group P < 0.05). Patients receiving Xuebijing achieved earlier enteral nutrition initiation (P = 0.0016) and a higher rate of day‑7 caloric targets (66.7% vs 49.4%, P = 0.031). Feeding intolerance showed a trend toward being lower in the Xuebijing group (24.14% vs 39.08%), but this difference did not reach statistical significance (P = 0.050); 28‑day mortality and adverse events also did not differ significantly between groups.
Conclusion:
Xuebijing use initiated within 24 hours of sepsis diagnosis in septic patients without pre-existing AGI was associated with protection of gastrointestinal function and improvement in several secondary outcomes, including lower AGI incidence, shorter hospital stays, reduced inflammation and organ dysfunction, and better enteral nutrition outcomes, without additional safety concerns. However, no significant difference in 28-day mortality was observed.